1. Availability and Pricing of New
Pharmaceuticals in the Top 5
European Pharmaceutical Markets
Reinaud F, Ando G (IHS, London, United Kingdom)
Objectives Among the innovative medicinal products available in each of the
top-five European pharmaceutical markets, manufacturer prices of
Pharmacoeconomics and cost-effectiveness assessments are 10 drugs were compared. For each drug, the ranking of the
increasingly taken into account in pricing and/or reimbursement markets studied from the highest manufacture price (1) to the
decisions. In an attempt to measure the impact those lowest (5) is summarised in the following table.
assessments have on time to pricing and price levels of innovative
Table 3: Ranking of the top-five European pharmaceutical markets
drugs, we surveyed market availability and drug prices for a
according to manufacturer price levels
basket of 125 innovative medicinal products in the top-five
European pharmaceutical markets. Brand name Germany Italy Spain UK France
Gilenya 1 3 5 2 4
Methods Vpriv
Ozurdex
1
1
5
5
3
4
2
2
5
3
The price availability of 125 innovative medicinal products— Revolade 2 1 3 5 4
approved between July 2009 and April 2012 by the EMA—in Onbrez Breezhaler 1 5 2 3 4
France, Germany, Italy, Spain, and the United-Kingdom was Ilaris 4 5 3 1 2
analysed. Cimzia 1 3 2 4 5
Onglyza 1 2 3 5 4
Manufacturer prices of 10 innovative drugs available in each of the Mozobil 3 1 4 5 2
markets studied were then compared. In order to do so, VAT, Eporatio 2 1 3 5 4
pharmacists’ margins, and wholesalers’ margins were removed Ranking Average 1.7 3.1 3.2 3.4 3.7
from retail prices provided by sources.
Source: IHS PharmOnline International; exchange rate UK: 1 GBP = 1.25367 EUR
Results Data indicate that prices of drugs are usually the highest in
Germany (they were the highest in 6 out of the 10 case studies). It
Table 1: Market availability of drugs in the top-five European pharmaceutical markets comes as no surprise considering that most drugs for which
out of the 125 innovative drugs approved by EMA between July 2009 and April 2012 prices were compared had been approved before the AMNOG
pricing reform, and none of them belongs to the 27 drugs that
Number of drugs available out of the
125 innovative drugs approved by Percentage completed the early benefit assessment.
EMA between July 2009 and April 2012
Prices of innovative drugs tend to be the lowest in France. This
Germany 74 59% result is unexpected given the fact that French legislation specifies
UK 67 54% that prices of drugs deemed innovative (ASMR ratings from I to III)
Spain 49 39% cannot be lower than the lowest price in Germany, Italy, Spain,
France 41 33% and the UK. However, the French National Authority for Health
Italy 40 32%
(HAS) is increasingly stringent when granting ASMR ratings, as
Source: IHS PharmOnline International
demonstrated by the annual activity reports: 18 ASMR from I to III
were granted in 2009. This figure dropped to 13 in 2010 and only
A limited number of the innovative drugs (17) included in the
1 in 2011.
sample analysed are available in each of the top-five European
pharmaceutical markets, although most of them were approved
by EMA at least year years ago. Conclusions
Table 2: Listing of the innovative medicinal products approved by EMA between As summarised in the following chart, Germany is where the most
July 2009 and April 2012 available in each of the top-five European pharmaceutical markets
innovative drugs are available and prices are the highest.
Brand name Marketing approval date Conversely, France has fewer innovative drugs available—due to
longer pricing procedures—and the lowest prices—due to the
Gilenya 17/03/2011
increasingly stringent assessment of drug innovation provided by
Jevtana 17/03/2011
the HAS. In Italy, Spain, and the UK, price levels differ on a case-
Vpriv 26/08/2010
by-case basis. In the UK, more drugs are available, while in Italy,
Ozurdex 27/07/2010
prices of orphan drugs tend to be higher.
Votrient 14/06/2010
Nivestim 08/06/2010
Menveo 15/03/2010
Revolade 11/03/2010
Prevenar 13 09/12/2009
Onbrez Breezhaler 30/11/2009
Multaq 26/11/2009
Eporatio 29/10/2009
Ilaris 23/10/2009
Resolor 15/10/2009
Cimzia 01/10/2009
Onglyza 01/10/2009
Mozobil 31/07/2009
Source: European Medicines Agency (EMA) and IHS PharmOnline International
FOR MORE INFORMATION ABOUT IHS GLOBAL INSIGHT HEALTHCARE & PHARMACEUTICAL SERVICES
www.ihs.com/healthcare and www.ihs.com/healthcareblog
Please email: gustav.ando@ihs.com for any questions related to this poster